Yale-New Haven Hospital
- Type
- Teaching hospital
- Where
- NEW HAVEN, CT
- Medicare CCN
- 070022
- Received
- $1,414,381 in 187 records, 2023 ($217,344 general, $1,197,037 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Yale New Haven Hospital, Inc. Fuzzy (name and state)
- Business registration: Yale New Haven Hospital, Inc. Fuzzy (name and state)
- Nonprofit contractor: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
- Plan sponsor: YALE-NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Federal award recipient: YALE NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Lobbying client: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
- Lobbying client: YALE-NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Lobbying registrant: YALE-NEW HAVEN HOSPITAL Fuzzy (name and state)
- Nonprofit: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 54 | $217,344 |
| 2023 | Research payment | 133 | $1,197,037 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| SEAGEN INC. | 96 | $271,995 | 2023 |
| Novartis Pharmaceuticals Corporation | 9 | $265,797 | 2023 |
| GENZYME CORPORATION | 4 | $229,936 | 2023 |
| Gen-Probe, Inc. | 4 | $142,826 | 2023 |
| Sage Therapeutics, LLC | 1 | $119,200 | 2023 |
| TransMedics, Inc. | 7 | $107,249 | 2023 |
| National Marrow Donor Program | 4 | $60,075 | 2023 |
| PFIZER INC. | 17 | $53,239 | 2023 |
| Genentech USA, Inc. | 1 | $25,000 | 2023 |
| E.R. Squibb & Sons, L.L.C. | 3 | $22,200 | 2023 |
| Draeger Medical Systems, Inc | 2 | $17,974 | 2023 |
| GE HEALTHCARE | 1 | $16,860 | 2023 |
| CTI BioPharma Corp. | 1 | $15,000 | 2023 |
| KLS-Martin L.P. | 2 | $10,053 | 2023 |
| AstraZeneca Pharmaceuticals LP | 4 | $10,000 | 2023 |
| ClearPoint Neuro, Inc. | 1 | $8,599 | 2023 |
| Stryker Corporation | 1 | $8,411 | 2023 |
| Indivior Inc. | 6 | $5,438 | 2023 |
| Incyte Corporation | 1 | $5,000 | 2023 |
| Lilly USA, LLC | 1 | $5,000 | 2023 |
| Eisai Inc. | 1 | $5,000 | 2023 |
| Olympus America Inc. | 7 | $3,091 | 2023 |
| Eli Lilly and Company | 1 | $2,248 | 2023 |
| Abbott Laboratories | 1 | $2,210 | 2023 |
| Barco, Inc. | 1 | $1,092 | 2023 |
| Alexion Pharmaceuticals, Inc. | 6 | $636 | 2023 |
| ARRAY BIOPHARMA INC | 2 | $150 | 2023 |
| Grifols Diagnostic Solutions, Inc. | 2 | $96 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 133 | $1,197,037 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 16 | $110,711 |
| Space rental or facility fees (teaching hospital only) | 2 | $40,000 |
| Grant | 4 | $27,200 |
| Education | 21 | $16,596 |
| Debt forgiveness | 9 | $13,145 |
| Long term medical supply or device loan | 2 | $9,691 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-20 | SEAGEN INC. | $1,950 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2023 |
| 2023-12-18 | SEAGEN INC. | $10,189 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-12-13 | SEAGEN INC. | $5,200 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-12-13 | Alexion Pharmaceuticals, Inc. | $140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-12-08 | Draeger Medical Systems, Inc | $17,791 | Research payment | Cash or cash equivalent | STIMIT Activator 1 Pivotal Study (NCT05883163) | 2023 | |
| 2023-11-17 | Abbott Laboratories | $2,210 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Vascular | Evaluation of Treatment Strategies for Severe Calcific Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplas | 2023 |
| 2023-11-15 | SEAGEN INC. | $5,000 | Education | Cash or cash equivalent | TUKYSA Drug, Oncology | 2023 | |
| 2023-11-15 | SEAGEN INC. | $5,000 | Education | Cash or cash equivalent | ADCETRIS Biological, Oncology | 2023 | |
| 2023-11-15 | SEAGEN INC. | $2,340 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2023 |
| 2023-11-15 | SEAGEN INC. | $1,745 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2023 |
| 2023-11-15 | SEAGEN INC. | $1,740 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2023 |
| 2023-11-15 | Indivior Inc. | $601 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | Coordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT) | 2023 |
| 2023-11-09 | SEAGEN INC. | $250 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-11-08 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | TIVDAK Biological, Oncology | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2023 |
| 2023-11-07 | Indivior Inc. | $1,033 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults | 2023 |
| 2023-11-03 | Stryker Corporation | $8,411 | Research payment | Cash or cash equivalent | TRIATHLON Device, KNEES | DOES THE SIZE OF THE COMPONENTS USED VARY WHEN ROBOTIC TKA IS PERFORMED COMPARED TO MANUAL TKA? | 2023 |
| 2023-11-02 | SEAGEN INC. | $780 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2023 |
| 2023-11-02 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-10-29 | Olympus America Inc. | $11 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-10-27 | Sage Therapeutics, LLC | $119,200 | Research payment | Cash or cash equivalent | ZULRESSO Drug, PSYCHIATRY/PSYCHOLOGY | Utility of Brexanolone to target stress-induced alcohol use among men and women with Posttraumatic Stress Disorder | 2023 |
| 2023-10-25 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-10-20 | National Marrow Donor Program | $19,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-10-20 | TransMedics, Inc. | $250 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART CAP | 2023 |
| 2023-10-11 | Alexion Pharmaceuticals, Inc. | $151 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-10-11 | SEAGEN INC. | $146 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-10-10 | Novartis Pharmaceuticals Corporation | $36,226 | Research payment | Cash or cash equivalent | KISQALI Drug, Oncology | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | 2023 |
| 2023-10-04 | E.R. Squibb & Sons, L.L.C. | $15,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-10-04 | SEAGEN INC. | $730 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-10-03 | Novartis Pharmaceuticals Corporation | $600 | Research payment | In-kind items and services | A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients Wit | 2023 | |
| 2023-10-03 | Draeger Medical Systems, Inc | $182 | Research payment | Cash or cash equivalent | STIMIT Activator 1 Pivotal Study (NCT05883163) | 2023 | |
| 2023-09-28 | TransMedics, Inc. | $16,140 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | OCSHEART-01-ClinPAS | 2023 |
| 2023-09-20 | SEAGEN INC. | $996 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2023 |
| 2023-09-20 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-09-20 | Alexion Pharmaceuticals, Inc. | $137 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-09-15 | TransMedics, Inc. | $54,129 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | OCSHEART-01-ClinPAS | 2023 |
| 2023-09-13 | SEAGEN INC. | $4,615 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-09-13 | SEAGEN INC. | $2,600 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-09-13 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-09-13 | SEAGEN INC. | $650 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-09-06 | SEAGEN INC. | $5,850 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-09-06 | SEAGEN INC. | $3,289 | Research payment | Cash or cash equivalent | TIVDAK Biological, Oncology | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2023 |
| 2023-09-06 | SEAGEN INC. | $2,891 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-09-06 | SEAGEN INC. | $1,788 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-09-06 | SEAGEN INC. | $585 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-09-06 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | TIVDAK Biological, Oncology | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2023 |
| 2023-09-06 | Alexion Pharmaceuticals, Inc. | $35 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-09-05 | PFIZER INC. | $75 | Education | In-kind items and services | 2023 | ||
| 2023-09-05 | PFIZER INC. | $75 | Education | In-kind items and services | 2023 | ||
| 2023-09-01 | Lilly USA, LLC | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-08-24 | GENZYME CORPORATION | $53,062 | Research payment | Cash or cash equivalent | XENPOZYME Biological, Genetic Disease | Understanding the role of sphingomyelin and lyso-sphingomyelin accumulation in pathogenesis of Niemann Pick type B disea | 2023 |
| 2023-08-24 | GENZYME CORPORATION | $53,062 | Research payment | Cash or cash equivalent | XENPOZYME Biological, Genetic Disease | Understanding the role of sphingomyelin and lyso-sphingomyelin accumulation in pathogenesis of Niemann Pick type B disea | 2023 |
| 2023-08-24 | GENZYME CORPORATION | $53,062 | Research payment | Cash or cash equivalent | XENPOZYME Biological, Genetic Disease | Understanding the role of sphingomyelin and lyso-sphingomyelin accumulation in pathogenesis of Niemann Pick type B disea | 2023 |
| 2023-08-23 | SEAGEN INC. | $876 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-08-23 | SEAGEN INC. | $650 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2023 |
| 2023-08-23 | Alexion Pharmaceuticals, Inc. | $140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-08-21 | GE HEALTHCARE | $16,860 | Research payment | In-kind items and services | Vizamyl Drug, CORE IMAGING | 2023 | |
| 2023-08-16 | AstraZeneca Pharmaceuticals LP | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | IMFINZI Biological, Oncology | 2023 | |
| 2023-08-16 | AstraZeneca Pharmaceuticals LP | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ENHERTU Biological, Oncology | 2023 | |
| 2023-08-16 | AstraZeneca Pharmaceuticals LP | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2023 | |
| 2023-08-16 | AstraZeneca Pharmaceuticals LP | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2023 | |
| 2023-08-16 | ARRAY BIOPHARMA INC | $75 | Education | In-kind items and services | 2023 | ||
| 2023-08-16 | PFIZER INC. | $75 | Education | In-kind items and services | 2023 | ||
| 2023-08-15 | PFIZER INC. | $75 | Education | In-kind items and services | 2023 | ||
| 2023-08-09 | SEAGEN INC. | $2,600 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-08-09 | SEAGEN INC. | $2,250 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2023 |
| 2023-08-09 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-08-09 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-08-08 | CTI BioPharma Corp. | $15,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Vonjo Drug, Hematology | 2023 | |
| 2023-08-07 | Indivior Inc. | $1,298 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults | 2023 |
| 2023-08-07 | PFIZER INC. | $75 | Education | In-kind items and services | 2023 | ||
| 2023-08-04 | National Marrow Donor Program | $24,410 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-08-02 | E.R. Squibb & Sons, L.L.C. | $6,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-08-02 | SEAGEN INC. | $1,788 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-08-02 | E.R. Squibb & Sons, L.L.C. | $1,200 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-08-02 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-08-01 | PFIZER INC. | $75 | Education | In-kind items and services | 2023 | ||
| 2023-07-26 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-07-26 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-07-26 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-07-26 | PFIZER INC. | $150 | Education | In-kind items and services | 2023 | ||
| 2023-07-26 | ARRAY BIOPHARMA INC | $75 | Education | In-kind items and services | 2023 | ||
| 2023-07-25 | PFIZER INC. | $75 | Education | In-kind items and services | 2023 | ||
| 2023-07-24 | PFIZER INC. | $300 | Education | In-kind items and services | 2023 | ||
| 2023-07-24 | PFIZER INC. | $75 | Education | In-kind items and services | 2023 | ||
| 2023-07-24 | PFIZER INC. | $75 | Education | In-kind items and services | 2023 | ||
| 2023-07-24 | PFIZER INC. | $75 | Education | In-kind items and services | 2023 | ||
| 2023-07-24 | PFIZER INC. | $75 | Education | In-kind items and services | 2023 | ||
| 2023-07-24 | PFIZER INC. | $75 | Education | In-kind items and services | 2023 | ||
| 2023-07-19 | SEAGEN INC. | $6,614 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-07-19 | SEAGEN INC. | $5,364 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-07-19 | SEAGEN INC. | $1,788 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-07-19 | SEAGEN INC. | $1,788 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-07-19 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-07-19 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-07-19 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-07-19 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-07-19 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-07-19 | SEAGEN INC. | $250 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2023 |
| 2023-07-19 | Alexion Pharmaceuticals, Inc. | $33 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-07-17 | SEAGEN INC. | $8,400 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-07-17 | SEAGEN INC. | $5,750 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-07-17 | SEAGEN INC. | $1,170 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-07-17 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-07-17 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-07-17 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-07-12 | PFIZER INC. | $12,837 | Research payment | Cash or cash equivalent | A PHASE 1 RANDOMIZED OPENLABEL 3PERIOD CROSSOVER SINGLEDOSE 2PART STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE EFFEC | 2023 | |
| 2023-07-12 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-06-28 | Eisai Inc. | $5,000 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-06-28 | SEAGEN INC. | $650 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2023 |
| 2023-06-28 | SEAGEN INC. | $650 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2023 |
| 2023-06-26 | GENZYME CORPORATION | $70,749 | Research payment | Cash or cash equivalent | XENPOZYME Biological, Genetic Disease | Understanding the role of sphingomyelin and lyso-sphingomyelin accumulation in pathogenesis of Niemann Pick type B disea | 2023 |
| 2023-06-23 | PFIZER INC. | $35,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-06-19 | Gen-Probe, Inc. | $3,009 | Research payment | Cash or cash equivalent | PANTHER FUSION Device, Diagnostics | Method Comparison Study Protocol for the Panther Fusion GI Panels | 2023 |
| 2023-06-07 | Indivior Inc. | $865 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults | 2023 |
| 2023-06-02 | SEAGEN INC. | $500 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-05-30 | SEAGEN INC. | $1,170 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2023 |
| 2023-05-22 | Gen-Probe, Inc. | $22,367 | Research payment | Cash or cash equivalent | PANTHER FUSION Device, Diagnostics | Method Comparison Study Protocol for the Panther Fusion GI Panels | 2023 |
| 2023-05-17 | Genentech USA, Inc. | $25,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Phesgo Biological, BioOncology | 2023 | |
| 2023-05-17 | SEAGEN INC. | $10,728 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-05-17 | SEAGEN INC. | $9,477 | Research payment | Cash or cash equivalent | TIVDAK Biological, Oncology | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2023 |
| 2023-05-17 | SEAGEN INC. | $1,856 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2023 |
| 2023-05-17 | SEAGEN INC. | $675 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2023 |
| 2023-05-17 | SEAGEN INC. | $250 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2023 |
| 2023-05-17 | SEAGEN INC. | $146 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-05-17 | SEAGEN INC. | $146 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-05-10 | SEAGEN INC. | $5,200 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2023 |
| 2023-05-10 | Eli Lilly and Company | $2,248 | Research payment | In-kind items and services | EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIEN | 2023 | |
| 2023-05-10 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-05-10 | SEAGEN INC. | $1,170 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-05-10 | SEAGEN INC. | $1,170 | Research payment | Cash or cash equivalent | TIVDAK Biological, Oncology | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2023 |
| 2023-05-10 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-05-03 | SEAGEN INC. | $16,049 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-05-03 | SEAGEN INC. | $1,560 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2023 |
| 2023-05-03 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2023 |
| 2023-05-01 | Grifols Diagnostic Solutions, Inc. | $48 | Education | In-kind items and services | 2023 | ||
| 2023-05-01 | Grifols Diagnostic Solutions, Inc. | $48 | Education | In-kind items and services | 2023 | ||
| 2023-04-28 | National Marrow Donor Program | $8,980 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-04-17 | Gen-Probe, Inc. | $10,500 | Research payment | Cash or cash equivalent | PANTHER FUSION Device, Diagnostics | Method Comparison Study Protocol for the Panther Fusion GI Panels | 2023 |
| 2023-04-11 | Indivior Inc. | $1,038 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | Coordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT) | 2023 |
| 2023-04-04 | Barco, Inc. | $1,092 | Long term medical supply or device loan | In-kind items and services | 2023 | ||
| 2023-03-23 | PFIZER INC. | $4,052 | Research payment | Cash or cash equivalent | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED 4PERIOD CROSSOVER FIRSTINHUMAN STUDY TO EVALUATE THE SAFE | 2023 | |
| 2023-03-22 | SEAGEN INC. | $19,640 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-03-22 | SEAGEN INC. | $18,172 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-03-22 | SEAGEN INC. | $5,364 | Research payment | Cash or cash equivalent | A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | 2023 | |
| 2023-03-22 | SEAGEN INC. | $2,016 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2023 |
| 2023-03-22 | SEAGEN INC. | $1,200 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2023 |
| 2023-03-22 | SEAGEN INC. | $780 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-03-20 | Gen-Probe, Inc. | $106,950 | Research payment | Cash or cash equivalent | PANTHER FUSION Device, Diagnostics | Method Comparison Study Protocol for the Panther Fusion GI Panels | 2023 |
| 2023-03-17 | TransMedics, Inc. | $5,460 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART TRIAL | 2023 |
| 2023-03-17 | SEAGEN INC. | $2,636 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-03-17 | SEAGEN INC. | $1,300 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-03-17 | SEAGEN INC. | $650 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-03-03 | Olympus America Inc. | $11 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-03-03 | Olympus America Inc. | $1 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-03-03 | Olympus America Inc. | $1 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-03-03 | Olympus America Inc. | $0 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-02-28 | Olympus America Inc. | $2,000 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-02-28 | Olympus America Inc. | $1,066 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-02-23 | TransMedics, Inc. | $26,520 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART CAP | 2023 |
| 2023-02-23 | TransMedics, Inc. | $4,500 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART TRIAL | 2023 |
| 2023-02-23 | TransMedics, Inc. | $250 | Research payment | Cash or cash equivalent | ORGAN CARE SYSTEM Device, DEVICE | DCD HEART CAP | 2023 |
| 2023-02-22 | SEAGEN INC. | $146 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-02-22 | SEAGEN INC. | $146 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-02-20 | Novartis Pharmaceuticals Corporation | $18,119 | Research payment | Cash or cash equivalent | KISQALI Drug, Oncology | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | 2023 |
| 2023-02-15 | SEAGEN INC. | $4,529 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-02-15 | SEAGEN INC. | $2,354 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-02-15 | SEAGEN INC. | $146 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-02-13 | SEAGEN INC. | $43,771 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-02-13 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-02-13 | SEAGEN INC. | $375 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2023 | |
| 2023-02-09 | KLS-Martin L.P. | $7,858 | Debt forgiveness | Cash or cash equivalent | IPS,IMPLANT, CRANIAL, 00088,CP TITANIUM,QTY:001 EA Device, Osteosynthesis | 2023 | |
| 2023-02-09 | KLS-Martin L.P. | $2,195 | Debt forgiveness | Cash or cash equivalent | IPS,SUPPLEMENTAL MODEL, FULL, 00007,QTY:001 EA Device, Osteosynthesis | 2023 | |
| 2023-02-08 | SEAGEN INC. | $2,016 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without | 2023 |
| 2023-01-27 | National Marrow Donor Program | $7,585 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-01-12 | Indivior Inc. | $601 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | Coordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT) | 2023 |
| 2023-01-09 | Novartis Pharmaceuticals Corporation | $130,353 | Research payment | Cash or cash equivalent | KISQALI Drug, Oncology | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | 2023 |
| 2023-01-09 | Incyte Corporation | $5,000 | Education | Cash or cash equivalent | 2023 | ||
| 2023-01-04 | SEAGEN INC. | $146 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-01-04 | SEAGEN INC. | $146 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2023 |
| 2023-01-04 | SEAGEN INC. | $146 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-01-04 | SEAGEN INC. | $146 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2023 |
| 2023-01-01 | Novartis Pharmaceuticals Corporation | $75,096 | Research payment | Cash or cash equivalent | Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investiga | 2023 | |
| 2023-01-01 | ClearPoint Neuro, Inc. | $8,599 | Long term medical supply or device loan | In-kind items and services | CLEARPOINT Device, Neurology | 2023 | |
| 2023-01-01 | Novartis Pharmaceuticals Corporation | $2,916 | Research payment | In-kind items and services | A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymp | 2023 | |
| 2023-01-01 | Novartis Pharmaceuticals Corporation | $1,920 | Research payment | In-kind items and services | A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax | 2023 | |
| 2023-01-01 | Novartis Pharmaceuticals Corporation | $345 | Research payment | In-kind items and services | A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for th | 2023 | |
| 2023-01-01 | Novartis Pharmaceuticals Corporation | $220 | Research payment | In-kind items and services | A randomized, double-blind, placebo-controlled phase II multi-center study of intravenous MBG453 added to hypomethylatin | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In New Haven, CT, county South Central Connecticut Planning Region, CT, state Connecticut; placed by its city name.
| Measure | Place (city or town) New Haven, CT | County South Central Connecticut Planning Region, CT | State Connecticut |
|---|---|---|---|
| Population B01003 | 134,349 | 570,598 | 3,624,508 |
| Population, 2020 census P1 | 134,023 | - | 3,605,944 |
| Median age B01002 | 31.9 | 40.2 | 41.1 |
| Under 18 B01001 | 21.3% | 19.6% | 20.2% |
| 65 and over B01001 | 11.8% | 18.6% | 18.5% |
| Households B11001 | 54,773 | 230,673 | 1,434,007 |
| Foreign born B05002 | 18.0% | 13.7% | 15.7% |
| Median household income B19013 | $56,851 | $88,197 | $95,781 |
| Median family income B19113 | $68,668 | $115,384 | $122,706 |
| Per capita income B19301 | $36,242 | $49,766 | $55,915 |
| Poverty rate B17001 | 23.9% | 11.4% | 10.0% |
| Unemployment rate B23025 | 8.4% | 6.0% | 5.6% |
| Civilian labor force B23025 | 69,528 | 307,607 | 1,959,490 |
| Mean commute (minutes) B08013 | 21.5 | 23.5 | 26.5 |
| Bachelor's degree or higher B15003 | 38.9% | 42.0% | 42.5% |
| Housing units B25001 | 60,333 | 248,267 | 1,541,822 |
| Owner-occupied B25003 | 28.4% | 60.5% | 66.5% |
| Renters B25003 | 71.6% | 39.5% | 33.5% |
| Median home value B25077 | $287,100 | $353,100 | $366,900 |
| Median gross rent B25064 | $1,488 | $1,525 | $1,488 |
| White, not Hispanic B03002 | 30.0% | 58.5% | 61.9% |
| Black B03002 | 27.6% | 13.0% | 9.8% |
| Hispanic or Latino B03002 | 31.0% | 19.5% | 18.3% |
| Asian B03002 | 5.2% | 4.5% | 4.7% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.1% |
Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Haven, CT.
Comments